Non-autoimmune hemolytic anemia
diseaseOn this page
Also known as Non-Autoimmune Hemolytic Anaemia
Summary
Non-autoimmune hemolytic anemia (MONDO:0021559) is a disease with 30 GWAS associations across 13 studies. A subtype of hemolytic anemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 30
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | non-autoimmune hemolytic anemia |
| Mondo ID | MONDO:0021559 |
| EFO | EFO:0005558 |
| NCIT | C34853 |
| SNOMED CT | 191216004 |
| UMLS | C0028283 |
| MedGen | 45122 |
| GARD | 0025337 |
| Is cancer (heuristic) | no |
Also known as: Non-Autoimmune Hemolytic Anaemia · Non-autoimmune hemolytic anaemia · non-autoimmune hemolytic anemia
Data availability: 30 GWAS associations (13 studies).
Disease family
This is a subtype of hemolytic anemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › hematologic disorder › anemia › normocytic anemia › hemolytic anemia › non-autoimmune hemolytic anemia
Related subtypes (10): familial hemolytic anemia, Heinz body anemia, lethal hemolytic anemia-genital anomalies syndrome, hemolytic disease of the newborn with Kell alloimmunization, hereditary elliptocytosis, Shiga toxin-associated hemolytic uremic syndrome, hereditary stomatocytosis, autoimmune hemolytic anemia, 6-phosphogluconate dehydrogenase deficiency, paroxysmal nocturnal hemoglobinuria
Genetics & variants
GWAS landscape
30 GWAS associations across 13 studies. Top hits map to 8 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| chr11:5227002 | 3e-174 | A | 2.36 | |
| chr11:5225678 | 4e-31 | ? | 3.29 | |
| chr16:183527 | 1e-17 | A | 4.61 | |
| rs540777345 | 5e-15 | SHH - Y_RNA | A | 3.29 |
| rs139185914 | 2e-14 | WDR12 | G | 3.85 |
| rs532423545 | 1e-12 | DTWD2 - DMXL1-DT | C | 3.96 |
| rs547042292 | 4e-12 | RPS3AP2 - PTX4 | C | 3.46 |
| rs139069715 | 5e-12 | ZBTB43 | A | 2.56 |
| rs192783417 | 9e-12 | EQTN - MOB3B | G | 1.95 |
| rs528614056 | 9e-12 | IFTAP - RPL7AP56 | C | 4.02 |
| rs181512541 | 1e-11 | CNTLN | C | 3.23 |
| rs576531990 | 1e-11 | SBF2-AS1, SBF2 | G | 3.27 |
| rs555460019 | 1e-11 | ADGRA2 | G | 1.89 |
| rs192124571 | 2e-11 | RNA5SP94 - MIR4432HG | C | 3.35 |
| rs113372935 | 3e-11 | CD300A - CD300LB | G | 3.63 |
| rs76198578 | 3e-11 | NCR2 - FOXP4-AS1 | C | 2.09 |
| rs113812918 | 4e-11 | PRKCZ | C | 3.65 |
| rs180692929 | 4e-11 | COMMD8 - ATP10D | G | 3.42 |
| rs554097462 | 4e-11 | LINC01448 - TCP1P1 | C | 2.91 |
| rs7545849 | 9e-10 | CYP2J2 | ? | |
| chrX:121856594 | 2e-09 | C | 3.34 | |
| chr16:5774329 | 1e-08 | G | 4.02 | |
| chr17:3229641 | 2e-08 | A | 4.13 | |
| chrX:84219832 | 2e-08 | G | 2.95 | |
| chr22:27055505 | 3e-08 | T | 4.5 | |
| chr8:77075851 | 3e-08 | T | 3.65 | |
| chr11:112560111 | 3e-08 | A | 4.57 | |
| chr16:3622090 | 3e-08 | T | 4.51 | |
| chr13:62379339 | 5e-08 | A | 4.56 | |
| chr11:5226943 | inf | ? | 3.46 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90473121 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 847 | 457,593 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90667918 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 847 | 457,593 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473120 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 722 | 8,493 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90477453 | Verma A | 2024 | 687 | 449,900 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90726705 | Kim HI | 2026 | 516 | 43,510 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90473127 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 366 | 458,074 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90479967 | Verma A | 2024 | 273 | 121,331 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90481654 | Verma A | 2024 | 273 | 121,331 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90727234 | Kim HI | 2026 | 251 | 43,775 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90473122 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 244 | 9,369 | Whole-genome sequencing of 490,640 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 1 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 29 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 16 |
| unknown | 13 |
Functional consequences
| Consequence | Count |
|---|---|
| unknown | 13 |
| intron_variant | 9 |
| intergenic_variant | 6 |
| synonymous_variant | 1 |
| splice_polypyrimidine_tract_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| chr11:5226943 | Tier 4: intronic/intergenic | |||||||
| chr11:5227002 | 3e-174 | Tier 4: intronic/intergenic | ||||||
| chr11:5225678 | 4e-31 | Tier 4: intronic/intergenic | ||||||
| chr16:183527 | 1e-17 | Tier 4: intronic/intergenic | ||||||
| rs540777345 | 7 | 156014699 | A>G | 0 | intron_variant | SHH - Y_RNA | 5e-15 | Tier 4: intronic/intergenic |
| rs139185914 | 2 | 202902422 | G>A,C | 0 | intron_variant | WDR12 | 2e-14 | Tier 4: intronic/intergenic |
| rs532423545 | 5 | 119001506 | C>T | 0.001 | intergenic_variant | DTWD2 - DMXL1-DT | 1e-12 | Tier 4: intronic/intergenic |
| rs547042292 | 16 | 1483584 | C>A,G,T | 0 | intergenic_variant | RPS3AP2 - PTX4 | 4e-12 | Tier 4: intronic/intergenic |
| rs139069715 | 9 | 126818988 | A>T | 0.003 | intron_variant | ZBTB43 | 5e-12 | Tier 4: intronic/intergenic |
| rs192783417 | 9 | 27298121 | G>A | 0.005 | intron_variant | EQTN - MOB3B | 9e-12 | Tier 4: intronic/intergenic |
| rs528614056 | 11 | 37436741 | C>G | 0 | intergenic_variant | IFTAP - RPL7AP56 | 9e-12 | Tier 4: intronic/intergenic |
| rs181512541 | 9 | 17135713 | C>A,T | 0.001 | intron_variant | CNTLN | 1e-11 | Tier 4: intronic/intergenic |
| rs576531990 | 11 | 9800978 | G>C | 0 | intron_variant | SBF2-AS1, SBF2 | 1e-11 | Tier 4: intronic/intergenic |
| rs555460019 | 8 | 37824181 | G>A | 0.002 | intron_variant | ADGRA2 | 1e-11 | Tier 4: intronic/intergenic |
| rs192124571 | 2 | 59826128 | C>G,T | 0.001 | intron_variant | RNA5SP94 - MIR4432HG | 2e-11 | Tier 4: intronic/intergenic |
| rs113372935 | 17 | 74493857 | G>A | 0 | intergenic_variant | CD300A - CD300LB | 3e-11 | Tier 4: intronic/intergenic |
| rs76198578 | 6 | 41414845 | C>T | 0.001 | intergenic_variant | NCR2 - FOXP4-AS1 | 3e-11 | Tier 4: intronic/intergenic |
| rs113812918 | 1 | 2173976 | C>A,G,T | 0.001 | synonymous_variant | PRKCZ | 4e-11 | Tier 4: intronic/intergenic |
| rs180692929 | 4 | 47467501 | G>A | 0 | splice_polypyrimidine_tract_variant | COMMD8 - ATP10D | 4e-11 | Tier 2: splice/UTR |
| rs554097462 | 7 | 42765625 | C>G,T | 0 | intergenic_variant | LINC01448 - TCP1P1 | 4e-11 | Tier 4: intronic/intergenic |
| rs7545849 | 1 | 59910442 | G>A | 0.05 | intron_variant | CYP2J2 | 9e-10 | Tier 4: intronic/intergenic |
| chrX:121856594 | 2e-09 | Tier 4: intronic/intergenic | ||||||
| chr16:5774329 | 1e-08 | Tier 4: intronic/intergenic | ||||||
| chr17:3229641 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chrX:84219832 | 2e-08 | Tier 4: intronic/intergenic | ||||||
| chr22:27055505 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr8:77075851 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr11:112560111 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr16:3622090 | 3e-08 | Tier 4: intronic/intergenic | ||||||
| chr13:62379339 | 5e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
4 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Cortisone Acetate | Approved (phase 4) |
| Dexamethasone | Approved (phase 4) |
| Prednisolone | Approved (phase 4) |
| Prednisone | Approved (phase 4) |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.